Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine

Cancer Letters

Volumn 307, Issue 1, 2011, Pages 53-61

  Van Rite, Brent D ^a   Harrison, Roger G ^a  

^a University of Oklahoma   (United States)

Author keywords

5 fluorouracil; Breast cancer; Cytosine deaminase annexin V; Enzyme; Prodrug

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; HYBRID PROTEIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DISTANT METASTASIS; DRUG CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; TUMOR VASCULARIZATION;

ANNEXIN A5; ANTIMETABOLITES; AORTA; BREAST NEOPLASMS; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; ENDOTHELIUM, VASCULAR; FEMALE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; HUMANS; PHOSPHATIDYLSERINES; PRODRUGS; RECOMBINANT FUSION PROTEINS;

EID: 79957458577     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.016     Document Type: Article

References (34)

1. Wyatt M.D., Wilson D.M. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol. Life Sci. 2009, 66:788-799.
2. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
3. Cheung W.Y., Fralick R.A., Cheng S. The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy. Curr. Oncol. 2008, 15:234-236.
4. Cutler R., Blair A., Kelly M. Flucytosine kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther. 1978, 24:333-342.
5. Coelho V., Dernedde J., Petrausch U., Panjideh H., Fuchs H., Menzel C., Dubel S., Keilholz U., Thiel E., Deckert P. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Int. J. Oncol. 2007, 31:951-957.
6. Zamboni S., Mallano A., Flego M., Ascione A., Dupuis M.L., Gellini M., Barca S., Cianfriglia M. Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast. Int. J. Oncol. 2008, 32:1245-1251.
7. Del Vecchio S., Reynolds J.C., Carrasquillo J.A., Blasberg R.G., Neumann R.D., Lotze M.T., Bryant G.J., Farkas R.J., Larson S.M. Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res. 1989, 49:2783-2789.
8. Zeng H., Wei Q., Huang R., Chen N., Dong Q., Yang Y., Zhou Q. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter. J. Androl. 2007, 827-835.
9. Chaszczewska-Markowska M., Stebelska K., Sikorski A., Madej J., Opolski A., Ugorski M. Liposomal formulation of 5-fluorocytosine in suicide gene therapy with cytosine deaminase--for colorectal cancer. Cancer Lett. 2008, 262:164-172.
10. Huber B., Richards C., Austin E. Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann. NY Acad. Sci. 1994, 716:104-114.
11. Harris J., Gutierrez A., Hurst H., Sikora K., Lemoine N. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1994, 1:170-175.
12. Singh Y., Palombo M., Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem. 2008, 15:1802-1826.
13. Kievit E., Bershad E., Ng E., Sethna P., Dev I., Lawrence T., Rehemtulla A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999, 59:1417-1421.
14. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62:6132-6140.
15. Ran S., Thorpe P.E. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54:1479-1484.
16. Utsugi T., Schroit A.J., Connor J., Bucana C.D., Fidler I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991, 51:3062-3066.
17. Sugimura M., Donato R., Kakkar V.V., Scully M.F. Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul. Fibrin. 1994, 5:365-373.
18. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
19. Mallano A., Zamboni S., Carpinelli G., Santoro F., Flego M., Ascione A., Gellini M., Tombesi M., Podo F., Cianfriglia M. Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast. BMC Biotechnol. 2008, 8:68.
20. Zang X.P., Palwai N.R., Lerner M.R., Brackett D.J., Pento J.T., Harrison R.G. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res. 2006, 26:1745-1751.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Senter P.D., Su P.C., Katsuragi T., Sakai T., Cosand W.L., Hellstrom I., Hellstrom K.E. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjug. Chem. 1991, 2:447-451.
23. Van Rite B., Lazrak Y., Pagnon M., Palwai N., Neves L., McFetridge P., Harrison R. Enzyme prodrug therapy designed to target L-methioninase to the tumor vasculature. Cancer Lett. 2011, 301:177-184.
24. Hayden M., Linsley P., Wallace A., Marquardt H., Kerr D. Cloning, overexpression, and purification of cytosine deaminase from saccharomyces cerevisiae. Protein Expres. Purif. 1998, 12:173-184.
25. Basic Transport Phenomena in Biomedical Engineering 2007, Taylor & Francis Group, New York. R. Fournier (Ed.).
26. Lila A., Ishida T., Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm. Res. 2010, 1171-1183.
27. van Heerde W.L., Sakariassen K.S., Hemker H.C., Sixma J.J., Reutelingsperger C.P., de Groot P.G. Annexin V inhibits the procoagulant activity of matrices of TNF-stimulated endothelium under blood flow conditions. Arterioscler. Thromb. 1994, 14:824-830.
28. van Heerde W.L., Poort S., van't Veer C., Reutelingsperger C.P., de Groot P.G. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem. J. 1994, 302(Pt 1):305-312.
29. Kenis H., van Genderen H., Bennaghmouch A., Rinia H.A., Frederik P., Narula J., Hofstra L., Reutelingsperger C.P. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J. Biol. Chem. 2004, 279:52623-52629.
30. Erbs P., Regulier E., Kintz J., Leroy P., Poitevin Y., Exinger F., Jund R., Mehtali M. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000, 60:3813-3822.
31. Schönebeck J., Polak A., Fernex M., Scholer H. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973, 18:321-336.
32. Li S., Wang A., Jiang W., Guan Z. Pharmacokinetic characteristics and anticancer effects of 5-Fluorouracil loaded nanoparticles. BMC Cancer 2008, 8:103-111.
33. Wolf W., Presant C.A., Servis K.L., el-Tahtawy A., Albright M.J., Barker P.B., Ring R., Atkinson D., Ong R., King M., et al. Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA 1990, 87:492-496.
34. Xiong M., Kwon G. PEGylation of yeast cytosine deaminase for pretargeting. J. Pharm. Sci. 2005, 94:1249-1258.